Product Datasheet

CFT1946

Catalog No. **BP-02369** · CAS **2882165-79-7** · Form **free base** · Physical state **other** · Color **Off-white to light yellow** · Version **1.0** · Revision **2026-09-11**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
PROTACs; Raf	**Cancer**

Molecular formula	$C_{45}H_{49}F_2N_{11}O_9S$
Molecular weight	**958.0010**

STRUCTURE



DESCRIPTION

CFT1946 is an orally active and selective target ligand for BRAF kinase. CFT1946 is a degrader of mutant BRAFV600E, G469A, G466V and p61-BRAFV600E. CFT1946 can be used in tumor research.

BIOLOGICAL ACTIVITY

Tagarafdeg (CFT1946) (100 nM; 24 h) causes BRAFV600E degradation and inhibits MAPK Signaling with pERK loss in BRAFV600E cells but not in WT-BRAF cells Tagarafdeg (CFT1946) (0.3-10 mg/kg; PO; BID; 20 days) induces tumor regression in the BRAFV600E A375 xenograft mouse model with 10 mg/kg

SOLUBILITY

Soluble in DMSO

In vitro	DMSO : 100 mg/mL

REFERENCES

[1]. Yanke Liang. The Discovery and Characterization of CFT1946: A Potent, Selective, and Orally Bioavailable Degrader of Mutant BRAF for the Treatment of BRAF-driven Cancers. ANNUAL MEETING, American Association for Cancer Research, 2023.

[2]. Rudolph J, et al. Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies. Nature reviews. Drug discovery. 2026 Aug;25(8):595-618.

[3]. Kreger B T, et al. CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance. Cancer Research, 2026, 86(2):438-452.

Lot CoA and SDS are separate documents.